enGene appoints Ryan Daws as CFO with $440K salary, 232K stock option grant

enGene Therapeutics Inc.

Ryan Daws appointed CFO effective Nov 27, 2023; base salary $440,000, target bonus 40%.
One-time sign-on bonus of $143,500 payable Jan 2024; must repay if leaves within 1 year or terminated for cause.
Granted option for 232,000 common shares at fair market value on Nov 30, 2023; 25% vests on 1st anniversary, monthly thereafter.
Severance on termination without cause or for good reason: 12 months base salary, COBRA, prorated bonus, and partial equity acceleration.
On change in control termination: full equity acceleration plus 12 months base and target bonus.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ryan Daws

Chief Financial Officer

ENGN · enGene Therapeutics Inc.

Effective: 2023-11-27
Filed: December 13, 2023, 6:59 PM ET

On December 13, 2023, Ryan Daws, Chief Financial Officer of enGene Holdings Inc. (the “Company”), entered into an Executive Employment Agreement with enGene USA, Inc. (“enGene USA”), effective as of November 27, 2023 (the “Daws Employment Agreement”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ryan Daws was appointed as Chief Financial Officer at enGene Therapeutics Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On December 13, 2023, Ryan Daws, Chief Financial Officer of enGene Holdings Inc. (the “Company”), entered into an Executive Employment Agreement with enGene USA, Inc. (“enGene USA”), effective as of November 27, 2023 (the “Daws Employment Agreement”).

View on SEC.gov

enGene Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000929638-23-003423

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.